Afatinib
Back to searchMolecule Structure
Scientific Name
Afatinib
Description of the Drug
Afatinib is an antineoplastic agent used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with non-resistant EGFR mutations or resistance to platinum-based chemotherapy.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08916
http://www.drugbank.ca/drugs/DB08916
Brand Name(s)
Gilotrif, Giotrif
Company Owner(s)
Boehringer Ingelheim
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Epidermal growth factor receptor erbB1 | SINGLE PROTEIN | INHIBITOR | CHEMBL203 |
Receptor protein-tyrosine kinase erbB-2 | SINGLE PROTEIN | INHIBITOR | CHEMBL1824 |
Receptor protein-tyrosine kinase erbB-4 | SINGLE PROTEIN | INHIBITOR | CHEMBL3009 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL185621 | ||
PharmGKB | PA165981154 | ||
DrugBank | DB08916 | ||
PubChem: Thomson Pharma | 15180141 | ||
PubChem | 10184653 | ||
LINCS | LSM-43226 | ||
Nikkaji | J3.363.130H | J2.685.397D | |
PDBe | 0WM | ||
BindingDB | 50322823 | ||
EPA CompTox Dashboard | DTXSID20893451 | ||
DrugCentral | 4318 | ||
Brenda | 213442 | ||
ChemicalBook | CB12470923 | CB62507657 | |
Guide to Pharmacology | 5667 | ||
rxnorm | AFATINIB | GILOTRIF | AFATINIB DIMALEATE |
PubChem: Drugs of the Future | 57304398 | ||
ChEBI | 61390 | ||
ZINC | ZINC000003976838 |